REVIVA PHARMACEUTICALS HOLDINGS INC. - COMMON STO

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

16 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

14 11 2023 16:01:00 提供 Nasdaq GlobeNewswire

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

30 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

25 9 2023 06:00:00 提供 Nasdaq GlobeNewswire

Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

07 9 2023 06:00:00 提供 Nasdaq GlobeNewswire